Elicio Therapeutics (NASDAQ:ELTX) Coverage Initiated at B. Riley Financial

Posted by Brian Himes on Jun 10th, 2026

Analysts at B. Riley Financial assumed coverage on shares of Elicio Therapeutics (NASDAQ:ELTX – Get Free Report) in a research note issued to investors on Wednesday. The brokerage set a “buy” rating and a $27.00 price target on the stock. B. Riley Financial’s price target suggests a potential upside of 90.14% from the stock’s current price.

Several other analysts have also recently commented on the stock. Wall Street Zen cut shares of Elicio Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Rodman & Renshaw upgraded shares of Elicio Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 10th. LADENBURG THALM/SH SH began coverage on shares of Elicio Therapeutics in a research note on Wednesday, April 15th. They issued a “buy” rating and a $20.00 target price for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Elicio Therapeutics in a research note on Friday, April 24th. Finally, HC Wainwright reissued a “buy” rating and issued a $17.00 target price on shares of Elicio Therapeutics in a report on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.25.

View Our Latest Research Report on Elicio Therapeutics

Elicio Therapeutics Stock Up 4.8%

ELTX stock opened at $14.20 on Wednesday. Elicio Therapeutics has a one year low of $7.37 and a one year high of $14.97. The stock has a market capitalization of $271.08 million, a PE ratio of -5.92 and a beta of 1.13. The company has a debt-to-equity ratio of 5.75, a quick ratio of 2.24 and a current ratio of 2.24. The company has a fifty day moving average of $11.13 and a 200-day moving average of $9.83.

Elicio Therapeutics (NASDAQ:ELTX – Get Free Report) last released its earnings results on Monday, May 11th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.16). As a group, analysts expect that Elicio Therapeutics will post -1.87 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its position in shares of Elicio Therapeutics by 186.8% in the third quarter. Bank of America Corp DE now owns 3,585 shares of the company’s stock worth $39,000 after acquiring an additional 2,335 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Elicio Therapeutics by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 132,518 shares of the company’s stock worth $1,055,000 after acquiring an additional 2,832 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Elicio Therapeutics in the second quarter worth approximately $46,000. State Street Corp boosted its position in shares of Elicio Therapeutics by 20.9% in the fourth quarter. State Street Corp now owns 46,300 shares of the company’s stock worth $369,000 after acquiring an additional 8,000 shares during the last quarter. Finally, Summit Financial LLC acquired a new stake in shares of Elicio Therapeutics in the fourth quarter worth approximately $80,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Elicio Therapeutics

(Get Free Report)

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.